Abstract
Advancements in the management of un-resectable mCRC have been characterised by smallincremental improvements in overall survival whichnow extends beyond 2 years with the addition ofbiological agents to standard fluoropyrimidine-basedchemotherapy regimens. Today, a whole host of newlyidentified targeted therapeutic agents inhibiting one ormore key pathways are being evaluated in phase IIIclinicaltrials(includingafliberceptandregorafenib)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
